Abstract
We present a case of a patient with metastatic renal cell cancer (RCC) treated with hypofractionated radiotherapy while being treated with sunitinib. He received a single dose of 8 Gy of external beam radiation to a metastatic mass of several centimeters diameter in the right lateral ribs, followed by a second identical dose. Clinically, the patient achieved a nearly complete disappearance of the mass. We discuss the possible synergy between tyrosine kinase receptor inhibitors (TKRIs) and radiotherapy and the importance of dose fractionation.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / pharmacology*
-
Angiogenesis Inhibitors / therapeutic use
-
Bone Neoplasms / secondary
-
Carcinoma, Renal Cell / pathology
-
Carcinoma, Renal Cell / radiotherapy*
-
Disease Progression
-
Dose Fractionation, Radiation
-
Humans
-
Indoles / administration & dosage
-
Indoles / pharmacology*
-
Indoles / therapeutic use
-
Kidney Neoplasms / pathology
-
Kidney Neoplasms / radiotherapy*
-
Male
-
Middle Aged
-
Pleural Neoplasms / secondary
-
Pyrroles / administration & dosage
-
Pyrroles / pharmacology*
-
Pyrroles / therapeutic use
-
Radiation-Sensitizing Agents / pharmacology*
-
Sunitinib
Substances
-
Angiogenesis Inhibitors
-
Indoles
-
Pyrroles
-
Radiation-Sensitizing Agents
-
Sunitinib